CT模拟机的质量控制和质量保证检验

虚拟模拟定位过程涉及放射诊断影像、放射治疗计划设计和放射治疗定位等技术.文章主要论述了放射治疗虚拟定位对CT模拟机质量保证工作中影像质量检验和定位精度检验的要求与方法.     

Multicentre analysis of treatment planning information: Technical requirements,possible applications and a proposal

Digital data from 3‐D treatment planning computers is generally used for patient planning and then never considered again. However, such data contains enormous quantities of information regarding patient geometries, tissue outlining, treatment approaches and dose distributions. Were such data accessible from planning systems from multiple manufacturers, there would be substantial opportunities for undertaking quality assurance of radiotherapy clinical trials, prospective assessment of trial outcomes and basic treatment planning research and development. The technicalities of data exchange between planning systems are outlined, and previous attempts at producing systems capable of viewing and/or manipulating imaging and radiotherapy digital data reviewed. Development of a software system for enhancing the quality of Australasian clinical trials is proposed.     

乳腺癌术后胸壁及区域淋巴结复发的治疗

本文对我科1985年6月至1988年6月收治的52例乳腺癌术后复发病例进行了分析。全部病例均完成了放射治疗，其中39例与化疗联合。全组病例局部控制率为59．6％，1年及2年生存率分别为80．8％和51.9%，本文结果提示，单纯胸壁复发的病例，预后明显好于胸壁及区域淋巴结同时复发的病例（P＜0．05)，与化疗联合对局部控制率无影响，但能显著提高长期生存率（P＜O．01）。     

Hospital-related differences in breast cancer management

A retrospective review is presented of 1353 consecutivepatients with histopathologically confirmed invasive breast carcinoma treatedradically with curative intent during the decade 1980–89.None had received adjuvant systemic therapy with hormonesor prolonged chemotherapy. The distribution of lymph-node negative(N–) and lymph-node positive (N+) patients was 75%and 25%, respectively.The treatment and outcome were analysed as regardsconventional prognostic parameters, in particular considering the axillarylymph-node status and the responsible hospital category (GeneralMunicipal Hospitals (MH)) versus Comprehensive Cancer Center (CC)).The most striking difference was detected as regardsthe number of examined lymph nodes. The mediannumber of nodes described at the MH was7, as compared to 14 at the CC(p < 0.001). In patients with pT1 tumoursthe highest rate of lymph-node positivity was observedwhen 10 or more axillary nodes were removed.Adjuvant radiotherapy reduced the loco-regional recurrence rate inthe N– patients, whereas only the regional recurrenceswere reduced among the N+ patients. The five-and 10-year tumor-related survival rates were 86% and76%, respectively, with no difference between the MHand the CC.As life-prolonging adjuvant hormone therapy and chemotherapy isnow available for patients with axillary lymph nodemetastases, it is important that patients with breastcancer are operated adequately with the aim toremove at least 10 axillary lymph nodes. Athorough examination of the axillary content should beperformed by the pathologist, and the number ofresected lymph nodes and metastases should be reported.The establishment of nation-wide standard criteria for themanagement of breast cancer is recommended.     

Low-grade astrocytomas in children: evolving management strategies

Developments in imaging and in neurosurgical techniques over the past decade have substantially altered the management of children with low-grade astrocytoma. Indications for surgery have become more clearly defined, and a larger proportion of children undergo complete or subtotal resection than in the past. Fewer receive adjuvant therapy, even though the options in this regard are more numerous now and theoretically likely to result in less morbidity than conventional external beam radiotherapy.

This review will address in particular the correlations between location, imaging appearance, and behavior that need to be more widely appreciated, and present recommendations regarding the management of these tumors.     

Altered therapy schedules in postoperative treatment of patients with malignant gliomas

Results of altered therapy schedules obtained in postoperative treatment of 294 patients with malignant gliomas over last 20 years are presented. During this period 135 patients received Conventional Irradiation and Chemotherapy (CICH), 61 patients received Conventional Irradiation (CI), 59 patients received Split Course High Fractional Dose Irradiation (SCHFDI), and 39 patients received Twice a Day Accelerated Irradiation (TDAI). Actuarial survival rates at 2, 3 and 5 years were 19%, 7%, 0% respectively for patients treated with CICH, and they were 21%, 10%, 0% for CI group, 24%, 12%, 0% for SCHFDI option and 15%, 8%, 0% for TDAI schedule. According to the Cox proportional hazard model, only age was significant factor in prognosis.     

Metastasis to the iris in squamous cell lung cancer

A 72-year-old Japanese woman, suffering from squamous cell lung cancer with brain metastasis, underwent 2 courses of combination chemotherapy, consisting of cisplatin and vindesine. Although both the primary tumor and the brain metastasis regressed markedly, she developed left ocular pain with blurred vision. An abnormal mass was found in the left iris, and cytologic examination of the aqueous aspirate revealed a few malignant cells, which, when examined by electron microscopy, were considered to be derived from squamous cell carcinoma of the lung.     

放疗病房发生医院感染的原因分析

为了解放疗病房医院感染的发病情况，对1995年8月～1996年7月间所有的放疗科的160例住院病人进行回顾性分析。结果发现年医院感染发病率为19．4％（31／160），年例次发病率为21．3％（34／l160）。有无基础病的发病率差异显著，接受抗癌治疗的病人处在多种致病危险因素之中。以抑制免疫功能、降低抵抗力为主要致病原因。感染发生的疾病前三位为临床败血症、急性支气管炎、肺部感染。因此，提醒人们发生在放疗病房的医院感染有其特殊性，要加强对放疗科各级医务人员的医院感染知识的教育，以便对发生的感染能够及时、有效的控制。     

EB病毒VCA-IgA抗体水平与鼻咽癌病人远期疗效关系

目的：分析ＥＢ病毒血清学ＶＣＡ－ＩｇＡ抗体与鼻咽癌病人远期疗效关系，为临床治疗提供参考依据。方法：１９８５年本院病理确诊的５２２例鼻咽癌病人，按治疗前、后ＶＣＡ－ＩｇＡ抗体滴度分为三组：低滴度组（１：５～１：２０）、中滴度组（１：４０～１：８０）和高滴度组（１：１６０以上），随访１０年，比较生存率的异同。结果：治疗前鼻咽癌病人高滴度组１０年生存率低于低滴度组（Ｐ＜０．０５），但和中滴度组差别无显著性（Ｐ＞０．０５）。治疗后三组病人１０年生存率比较，高、中滴度二组差别无显著性（Ｐ＞０．０５），但低于低滴度组。结论：ＥＢ病毒ＶＣＡ－ＩｇＡ抗体水平可以作为估计预后的重要参考依据，与远期疗效有密切关系。     

同时持续输注化疗合并放疗治疗食管癌125例

目的观察同时静脉输注化疗在食管癌放疗中的增敏、增效作用。方法从1992年3月到1995年10月，我们共收治食管癌患者125例，随机分为两组，其中60例同时持续输注化疗合并放疗（观察组），65例单纯放疗（对照组），两组放疗剂量相同为50—65GY／5—6周。结果观察组在治疗结束时有效率（CR＋PR）为85．0％，对照组为72．3％，两组比较有显著性差异（P＜0．05）；2、3年生存率分别为观察组48．3％和28．3％，对照组36．9％和15．4％，有显著差异（P＜O．05）。结论同时持续输注化疗合并放疗可以提高食管癌放疗的疗效，对放疗有增敏、增效作用，从而延长食管瘤患者的生存时间。